www.piyarawatan.com 提示:

本信息仅供医学专业人士参考,如果您是医学专业人士,请点击确定后进入。 如果不是,请点击取消。

取消 确定

Strive to enable biopharmaceuticals created and
manufactured by China to benefit patients worldwide

Overview of the international registration and marketing of 3SBio Group products

At present, 3SBio products that are registered overseas include YISAIPU, TPIAO, EPIAO, Intefen and SEPO, etc. The registration has covered nearly 40 countries and regions around the world, with the business and customer scope basically covering all the developing countries. After years of hard work, these products have also been registered and listed in many countries.

  • Latin American region with Mexico, Colombia, Brazil, etc. being the centers
  • South Asia Region with India, Pakistan, Bangladesh and Sri Lanka being the centers
  • Southeast Asian region with Thailand, Indonesia, Philippines and Vietnam being centers
  • The Commonwealth of the Independent States (CIS) region with Russia, Belarus and Ukraine being centers
  • Middle Eastern & Northern Africa (MENA) region with Turkey and Egypt being centers

Clinical experience (important internationally published papers)

  • Application of Etanar® Therapy in Patients with Rheumatoid Arthritis

    Published at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR), Atlanta, Georgia, USA, in November 10, 2010.


    Abstract 1811. In the “real life” environment, the 20-week efficacy and safety analysis was conducted in the 110 patients who received Etanar® (25 mg, subcutaneous injection, twice a week) in combination with multiple DMARD anti-RA treatment for a long time.

  • ETANAR - Generic drug YISAIPU is as effective as adalimumab and infliximab in treating a group of patients with rheumatoid arthritis

    This article was published as a poster in EULARL 2015 (Rome, Italy) (P. Santos-Moreno et al. Ann Rheum Dis 2015; 74:789-790).


    The descriptive cross-sectional study included 158 RA patients who visited at least 6 rheumatologists within the past 24 months, and respectively received adalimumab (61 (38.6%), infliximab (35 (22.2 %) and YISAIPU biosimilar products (62 (39.2%) (Etanar® CP Guojian Pharmaceutical Co., Ltd. (China)).

  • Clinical Outcomes of Etanar - a New Biotype of rhTNFR:Fc in Colombian Patients with Rheumatoid Arthritis

    (PISantos-Moreno, G. Sánchez, D. Gómez, C. Castro. Clinical and Experimental Rheumatology, 2015; 33: 858-862.) A multicenter observational cohort study evaluated the clinical reactions at the 12th month in 105 RA patients treated with Etanar (rhTNFR:Fc) and the incidence of the adverse reactions was recorded.

  • Comparison of the direct effects of three anti-tumor necrosis factor biologics in the cohort of patients with rheumatoid arthritis

    (Pedro Santos-Moreno, Guillermo Sánchez, Danny Gómez. et al; JCR-Journal of Clinical Rheumatology, 2016; 22 (2):57-62) The observational retrospective cohort study compared the clinical reactions at 36 months after treatment in 307 RA patients who received YISAIPU (Etanar®), infliximab (Remecade®) or adalimumab (Humira®) and evaluated the adverse events.

International Business Department

Address: No. 399 Libing Road, Zhangjiang Hi-Tech Park, Shanghai, China. Post code: 201203

Email Address : international@piyarawatan.com

Tel: +86-21-50791399

电脑访问:k8凯发手机版 PC端 | 手机访问:k8凯发手机版 手机端
友情链接: